Soleno Therapeutics, Inc. (SLNO)

Market Cap	3.87B
Revenue (ttm)	n/a
Net Income (ttm)	-198.23M
Shares Out	50.39M
EPS (ttm)	-4.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	937,991
Open	77.74
Previous Close	76.26
Day's Range	76.62 - 78.45
52-Week Range	36.93 - 80.91
Beta	-2.67
Analysts	Strong Buy
Price Target	103.33 (+34.61%)
Earnings Date	May 7, 2025

About SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwoo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 13, 2014
• Employees: 92
• Stock Exchange: NASDAQ
• Ticker Symbol: SLNO
• Website: https://soleno.life

Analyst Forecast

According to 9 analysts, the average rating for SLNO stock is "Strong Buy." The 12-month stock price forecast is $103.33, which is an increase of 34.61% from the latest price.

Price Target

$103.33

(34.61% upside)

Analyst Consensus: Strong Buy